‘No one knows what is in these deals’: Trump set to announce new Medicaid drug pricing model amid affordability concerns

The Trump administration is poised to announce a significant new drug pricing initiative that would require "most favored nation" pricing for certain pharmaceuticals covered by Medicaid. The policy, expected to be rolled out Friday, will encompass all 50 states and aims to curb rising drug costs by linking U.S. prices to those paid in other developed countries.

A New Pricing Benchmark

The core of the proposal is the adoption of a "most favored nation" (MFN) model. This framework would prevent Medicaid from paying more for select drugs than the lowest price paid by a comparable foreign nation. By tying the net price to an international benchmark, the administration intends to leverage lower global prices to drive down domestic expenditures on prescription medications within the government-funded health program for millions of Americans.

Nationwide Implementation and Scope

According to the planned announcement, the policy will not be a limited pilot program; rather, it is set for implementation across all 50 states. This national scope suggests a broad effort to overhaul a key aspect of pharmaceutical reimbursement under Medicaid. The initiative will specifically target certain drugs, though the exact medications and the mechanism for their selection have not yet been detailed, creating a layer of uncertainty for the pharmaceutical industry.

Addressing Affordability Amid Uncertainty

The administration is framing this move as a direct response to concerns over drug affordability. However, the announcement comes with considerable ambiguity regarding its execution. The lack of specific details about which drugs will be included or how international price points will be calculated has left industry stakeholders and policy analysts awaiting further clarification. The success of the program will hinge on the fine print of the policy, which remains undisclosed, fueling questions about its potential market impact and operational feasibility for both states and drug manufacturers.